NCT05831124View on ClinicalTrials.gov

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

June 26, 2024

Study Completion Date

June 26, 2024

Conditions
Pneumococcal Disease
Interventions
OTHER

Low dose multivalent pneumococcal conjugate vaccine formulation A

Biological

OTHER

Low dose multivalent pneumococcal conjugate vaccine formulation B

Biological

BIOLOGICAL

Low dose of multivalent pneumococcal conjugate vaccine control

low dose multivalent pneumococcal conjugate vaccine

BIOLOGICAL

Standard dose multivalent pneumococcal conjugate vaccine control

multivalent pneumococcal conjugate vaccine

Trial Locations (9)

14609

Rochester Clinical Research, LLC, Rochester

21045

Centennial Medical Group, Columbia

21075

Centennial Medical Group, Elkridge

33012

Indago Research & Health Center, Inc, Hialeah

33024

Research Centers of America ( Hollywood ), Hollywood

Research Centers of America, Hollywood

68134

Velocity Clinical Research, Omaha, Omaha

78229

Clinical Trials of Texas, LLC dba Flourish Research, San Antonio

Clinical Trials of Texas, LLC, San Antonio

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05831124 - A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults | Biotech Hunter | Biotech Hunter